MBA MD - MEI Pharma Chief Officer

MEIP Stock  USD 2.31  0.01  0.43%   

Executive

MBA MD is Chief Officer of MEI Pharma
Age 66
Phone858 369 7100
Webhttps://meipharma.com

MEI Pharma Management Efficiency

The company has return on total asset (ROA) of (0.3068) % which means that it has lost $0.3068 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9368) %, meaning that it created substantial loss on money invested by shareholders. MEI Pharma's management efficiency ratios could be used to measure how well MEI Pharma manages its routine affairs as well as how well it operates its assets and liabilities.
MEI Pharma currently holds 8.36 M in liabilities with Debt to Equity (D/E) ratio of 0.18, which may suggest the company is not taking enough advantage from borrowing. MEI Pharma has a current ratio of 6.7, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about MEI Pharma's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Roman NecinaHookipa Pharma
57
Danielle OlanderMoghadassianCytomX Therapeutics
N/A
Barry MSOcular Therapeutix
N/A
William SlatteryOcular Therapeutix
N/A
Diana ChungTerns Pharmaceuticals
N/A
Jeffrey JasperTerns Pharmaceuticals
N/A
Daniel MDTranscode Therapeutics
73
Gayle GirondaInozyme Pharma
N/A
Steve MeyersOcular Therapeutix
N/A
MD FACCZyVersa Therapeutics
75
James TaylorAchilles Therapeutics PLC
63
William IIOcular Therapeutix
N/A
Adam DubowDay One Biopharmaceuticals
57
Scott HarrisTerns Pharmaceuticals
N/A
Alexander MBAVincerx Pharma
45
David BradyZura Bio Limited
N/A
Robert MBBSInstil Bio
N/A
Prof MDDay One Biopharmaceuticals
55
Daniel CourtneyHookipa Pharma
N/A
Lee SternAchilles Therapeutics PLC
N/A
Pattie ChiangKezar Life Sciences
N/A
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California. Mei Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 102 people. MEI Pharma (MEIP) is traded on NASDAQ Exchange in USA. It is located in 9920 Pacific Heights Blvd., San Diego, CA, United States, 92121 and employs 28 people. MEI Pharma is listed under Biotechnology category by Fama And French industry classification.

Management Performance

MEI Pharma Leadership Team

Elected by the shareholders, the MEI Pharma's board of directors comprises two types of representatives: MEI Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of MEI. The board's role is to monitor MEI Pharma's management team and ensure that shareholders' interests are well served. MEI Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, MEI Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
Justin CPA, CFO CEO
BA Esq, COO Counsel
Anne Frese, Chief Officer
Eugene Park, VP Marketing
Virginia Sankey, VP Fin
JD Esq, Chief Officer
Eric Deng, VP Operations
Richard Ghalie, Chief Officer
MBA MD, Chief Officer
LLM JD, Senior Affairs
Robert Mass, Chief Medical Officer
BA CPA, CFO Sec
Justin File, CFO Secretary
Nicole Iida, Vice Affairs
Daniel Gold, CEO and President and Director
Yomara GomezNaiden, Senior Quality

MEI Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is MEI Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Additional Tools for MEI Stock Analysis

When running MEI Pharma's price analysis, check to measure MEI Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MEI Pharma is operating at the current time. Most of MEI Pharma's value examination focuses on studying past and present price action to predict the probability of MEI Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MEI Pharma's price. Additionally, you may evaluate how the addition of MEI Pharma to your portfolios can decrease your overall portfolio volatility.